ReviewFrontiers in immunology2025
Advances in the multifunctionality of cell membrane-encapsulated nanoparticles in the treatment of colorectal cancer.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell membrane-camouflaged nanoparticles (CNPs) have emerged as promising multifunctional platforms for colorectal cancer therapy, integrating drug delivery, immunomodulation, photothermal ablation, and anti-inflammatory effects. This review highlights recent advances in CNP-based strategies, emphasizing their unique capacity to enhance tumor-targeting specificity, potentiate immunotherapeutic efficacy, and overcome the limitations of conventional treatments. We summarize diverse approaches employing immune cell or tumor cell membrane coatings, as well as hybrid systems that combine CNPs with chemotherapy, metabolic modulation, or photothermal therapy. Accumulating evidence demonstrates that CNPs can effectively remodel the tumor immune microenvironment, increase the bioavailability of hydrophobic drugs, and promote synergistic therapeutic outcomes. Despite these encouraging results, clinical translation remains constrained by challenges in biodegradability, biosafety, large-scale manufacturing, and cost. Ongoing clinical trials are evaluating the safety and therapeutic potential of CNP-based nanomedicines. Overall, this review underscores the transformative role of CNPs as a next-generation platform for precision and personalized therapy in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.